Fenclozic acid (Synonyms: ICI-54450; Acidum fenclozicum; Mialex)

Name: Fenclozic acid
Brand: MedChemExpress
SKU: HY-101432
Rating: 4.5 (1 reviews)

Cat. No.: HY-101432 Purity: 99.52%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Fenclozic acid (ICI-54450) is an orally active anti-inflammatory, analgesic, and antipyretic agent. Fenclozic acid exhibits anti-inflammatory activity in Edadjuvant-induced arthritis and Carrageenin-induced oedema in rats. Fenclozic acid can be used for the research of arthritis.

For research use only. We do not sell to patients.

Fenclozic acid Chemical Structure

CAS No. : 17969-20-9

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	Get quote
100 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

View All Isoforms

COX COX-1 COX-2 COX-3

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
Sf21	IC₅₀	> 1000 μM Compound: Fenclozic acid	Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of Sprague-Dawley rat Bsep expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]
Sf21	IC₅₀	> 1000 μM Compound: Fenclozic acid	Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake Inhibition of human BSEP expressed in plasma membrane vesicles of Sf21 cells assessed as inhibition of ATP-dependent [3H]taurocholate uptake	[PMID: 21965623]

In Vitro

Fenclozic acid (0.5-5 mM) is not significantly metabolized by isolated rat duodenal mucosal whole cells or homogenates, with <5% converted to a decarboxylated derivative^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Fenclozic acid (100 mg/kg; p.o.; two doses 15 hours apart; or daily for 6 days) increases rat liver tryptophan pyrrolase activity by approximately three-fold^[1].
Fenclozic acid (2.5-50 mg/kg; p.o.; daily; 14 days) exhibits anti-inflammatory activity in developing and establish edadjuvant-induced arthritis in rats^[2].
Fenclozic acid (10, 30, and 90 mg/kg; p.o.; single dose) exhibits anti-inflammatory activity in Carrageenin-induced oedema in rats^[2].
Fenclozic acid (25-100 mg/kg; p.o.; single dose) exhibits antipyretic activity in rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mature MRC-hooded rats (200-350g)^[1]
Dosage:	100 mg/kg
Administration:	p.o.; two doses 15 hours apart; or daily for 6 days
Result:	Increased tryptophan pyrrolase activity from a control level of 4.4 units/g liver to 13.7 units/g liver (two-dose regime). Increased tryptophan pyrrolase activity from a control level of 4.4 units/g liver to 14.0 units/g liver (six-day daily regime). Achieved an approximate three-fold increase in enzyme activity regardless of dose schedule.

Animal Model:	Male Alderley Park strain I (200 g) with arthritis induced by Adjuvant^[2]
Dosage:	2.5; 5; 10; 20; 25; 45; 50 mg/kg
Administration:	p.o.; daily; 14 days (starting 1 day before adjuvant injection)
Result:	Produced 41% inhibition of injected foot thickness increase on day 3 and 53% inhibition on day 14 at 20 mg/kg. Associated with improved body weight gain compared to untreated controls. Produced a dose-dependent decrease in foot thickness of both injected and non-injected hind feet over 14 days of treatment.

Animal Model:	Male Alderley Park strain I (200 g) with oedema induced by Carrageenin^[2]
Dosage:	10; 30; 90 mg/kg
Administration:	p.o.; single dose; 3 hours before Carrageenin injection
Result:	Produced a dose-dependent reduction in carrageenin-induced foot swelling.

Animal Model:	Male Alderley Park strain I (200 g) intravenously injected with Pertussis vaccine B.P. ^[2]
Dosage:	25; 50; 100 mg/kg
Administration:	p.o.; single dose; immediately before Pertussis vaccine injection
Result:	Completely prevented the pyrogen-induced increase in body temperature at 100 mg/kg. Partially suppressed the temperature rise at 50 mg/kg and 25 mg/kg doses.

Molecular Weight

253.70

Formula

C₁₁H₈ClNO₂S

CAS No.

17969-20-9

Appearance

Solid

Color

White to light yellow

SMILES

O=C(O)CC1=CSC(C2=CC=C(Cl)C=C2)=N1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (394.17 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.9417 mL	19.7083 mL	39.4166 mL
5 mM	0.7883 mL	3.9417 mL	7.8833 mL
10 mM	0.3942 mL	1.9708 mL	3.9417 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.85 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.52%

Select Batch:

Data Sheet (276 KB) SDS (392 KB)

COA (247 KB) HNMR (235 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Curtis CG, et al. The fate of fenclozic acid in the gut and its effect on some aspects of gut metabolism. Xenobiotica. 1983;13(8):483-496. [Content Brief]

[2]. Newbould BB, et al. The pharmacology of fenclozic acid (2-(4-chlorophenyl)-thiazol-4-ylacetic acid; I.C.I. 54,450; 'Myalex'); a new compound with anti-inflammatory, analgesic and antipyretic activityl. Br J Pharmacol. 1969;35(3):487-497. [Content Brief]

[3]. Martin S, et al. Identification of the reactive metabolites of fenclozic acid in bile duct cannulated rats. Anal Chem. 2014;86(22):11281-11289. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	3.9417 mL	19.7083 mL	39.4166 mL	98.5416 mL
	5 mM	0.7883 mL	3.9417 mL	7.8833 mL	19.7083 mL
	10 mM	0.3942 mL	1.9708 mL	3.9417 mL	9.8542 mL
	15 mM	0.2628 mL	1.3139 mL	2.6278 mL	6.5694 mL
	20 mM	0.1971 mL	0.9854 mL	1.9708 mL	4.9271 mL
	25 mM	0.1577 mL	0.7883 mL	1.5767 mL	3.9417 mL
	30 mM	0.1314 mL	0.6569 mL	1.3139 mL	3.2847 mL
	40 mM	0.0985 mL	0.4927 mL	0.9854 mL	2.4635 mL
	50 mM	0.0788 mL	0.3942 mL	0.7883 mL	1.9708 mL
	60 mM	0.0657 mL	0.3285 mL	0.6569 mL	1.6424 mL
	80 mM	0.0493 mL	0.2464 mL	0.4927 mL	1.2318 mL
	100 mM	0.0394 mL	0.1971 mL	0.3942 mL	0.9854 mL

Fenclozic acid Related Classifications

Inflammation/Immunology

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Fenclozic acid17969-20-9ICI-54450 Acidum fenclozicum MialexICI54450ICI 54450COXCyclooxygenaseadjuvant-induced arthritisHan Wistar ratsarthritisCarrageeninoedemaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Fenclozic acid (Synonyms: ICI-54450; Acidum fenclozicum; Mialex)

Customer Review

Fenclozic acid Related Antibodies

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All COX Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Fenclozic acid Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Fenclozic acid Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report